Eupatilin Ameliorates Sepsis‐Induced Myocardial Injury by Targeting the KAT5 ‐ H3K27la Epigenetic Axis
BioFactors · 2026
DOI: 10.1002/biof.70094 ↗Kurz gefasst
Fachartikel in der Zeitschrift BioFactors, 2026. Verfasst von Qianqian Du und 9 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Hubei University of Chinese Medicine, Wuhan, China. Hauptthemen laut MEDLINE: Sepsis, Histones, Flavonoids, Epigenesis, Genetic. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: Hubei Provincial Natural Science Foundation of China, Hubei Provincial Science and Technology Plan Project, Project of Hubei Province Traditional Chinese Medicine Innovation Team.
Themen: Sepsis
Abstract (Originalsprache)
Sepsis induced myocardial injury (SIMI) remains a life threatening complication with mortality rates exceeding 40% to 50%, yet effective therapies are lacking. This study investigates the cardioprotective effects of eupatilin (EUP), a bioactive flavonoid derived from Artemisia argyi, and reveals a previously unrecognized mechanism involving selective modulation of KAT5 mediated histone H3K27 lactylation (H3K27la). Using an LPS induced murine model and TNF‐α stimulated human AC16 cardiomyocytes, we evaluated cardiac function, inflammatory responses, and apoptotic pathways through dose response analyses. Multi omics approaches including RNA seq, metabolomics, ChIP seq, and molecular docking were integrated to dissect the pharmacodynamic profile of EUP. EUP conferred concentration dependent cardioprotection with optimal effects at 25 μM. Compared with conventional glucocorticoid therapy, EUP showed enhanced target selectivity, markedly reducing pro inflammatory cytokines such as TNF‐α, IL‐1β, and IL‐6 while improving cardiac function parameters including ejection fraction and fractional shortening. Mechanistically, EUP bound KAT5 with high affinity, suppressed its lactylation activity, and reduced H3K27la enrichment at the promoters of inflammatory genes. Metabolic flux analysis further indicated that EUP inhibited glycolytic lactate production and restored oxidative phosphorylation. Together, these findings identify EUP as a natural modulator of the KAT5‐H3K27la axis, addressing both metabolic dysregulation and epigenetic reprogramming in SIMI. With a favorable pharmacokinetic profile and superior target specificity relative to standard immunosuppressive regimens, EUP holds promise for clinical translation in sepsis associated cardiac dysfunction.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Hubei University of Chinese Medicine, Wuhan, China.
- School of Laboratory Medicine, Hubei University of Chinese Medicine, Wuhan, China.
- Hubei Shizhen Laboratory, Wuhan, China.
- State Key Laboratory of Trauma and Chemical Poisoning, Department of Wound Infection and Drug, Daping Hospital, Army Medical University, Chongqing, China.
- School of Electrical Engineering and Automation, Anhui University, Hefei, China.
ORCID-Profile: Huaping Liang, Kang Xu
Förderung
- Hubei Provincial Natural Science Foundation of China
- Hubei Provincial Science and Technology Plan Project
- Project of Hubei Province Traditional Chinese Medicine Innovation Team
Zitieren
APA
Du, Q., Hou, S., Liu, M., Wu, J., Yu, H., Feng, F., Liang, H., Wang, C., Xu, K., & Chi, Q. (2026). Eupatilin Ameliorates Sepsis‐Induced Myocardial Injury by Targeting the KAT5 ‐ H3K27la Epigenetic Axis. BioFactors. https://doi.org/10.1002/biof.70094
Vancouver
Du Q, Hou S, Liu M, Wu J, Yu H, Feng F, et al. Eupatilin Ameliorates Sepsis‐Induced Myocardial Injury by Targeting the KAT5 ‐ H3K27la Epigenetic Axis. BioFactors. 2026. doi:10.1002/biof.70094
BibTeX
@article{Du2026,
author = {Du, Qianqian and Hou, Shuwan and Liu, Minfu and Wu, Jiaqin and Yu, Huiming and Feng, Fan and Liang, Huaping and Wang, Chunli and Xu, Kang and Chi, Qingjia},
title = {Eupatilin Ameliorates Sepsis‐Induced Myocardial Injury by Targeting the KAT5 ‐ H3K27la Epigenetic Axis},
journal = {BioFactors},
year = {2026},
doi = {10.1002/biof.70094}
}
EUVIMED